| Literature DB >> 32027669 |
Meghan Maguire1,2, Michele Campaigne Larsen2, Chad M Vezina3, Loredana Quadro4, Youn-Kyung Kim4, Sherry A Tanumihardjo5, Colin R Jefcoate2.
Abstract
BACKGROUND: Cytochrome P450 1b1 (Cyp1b1) deletion and dietary retinol deficiency during pregnancy (GVAD) affect perinatal liver functions regulated by Srebp. Cyp1b1 is not expressed in perinatal liver but appears in the E9.5 embryo, close to sites of retinoic acid (RA) signaling. HYPOTHESIS: Parallel effects of Cyp1b1 and retinol on postnatal Srebp derive from effects in the developing liver or systemic signaling. APPROACH: Cluster postnatal increases in hepatic genes in relation to effects of GVAD or Cyp1b1 deletion. Sort expression changes in relation to genes regulated by Srebp1 and Srebp2.Test these treatments on embryos at E9.5, examining changes at the site of liver initiation. Use in situ hybridization to resolve effects on mRNA distributions of Aldh1a2 and Cyp26a1 (RA homeostasis); Hoxb1 and Pax6 (RA targets). Assess mice lacking Lrat and Rbp4 (DKO mice) that severely limits retinol supply to embryos.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32027669 PMCID: PMC7004353 DOI: 10.1371/journal.pone.0228436
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Shared postnatal effects on oleate and cholesterol pathways in GVAD-treated and Cyp1b1-/- pups extend to retinoic acid homeostasis.
| Gene | PN21/Birth | Regulator Pattern | WT GVAD/WT Suff | ||
|---|---|---|---|---|---|
| 8.6 | Srebp1 | -3.5 | -7.0 | -3.0 | |
| 87.0 | Srebp1 | -4.3 | -12.2 | -6.5 | |
| 4.0 | Srebp2 | NS | -6.4 | -1.5 | |
| 2.4 | Srebp2 | -2.2 | -23.0 | NS | |
| 7.3 | Srebp2 | NS | -4.7 | NS | |
| 1.6 | Srebp2 | NS | -2.3 | NS | |
| 2.8 | Srebp2 | NS | -1.9 | NS | |
| 15 | Srebp2 | NS | -2.7 | NS | |
| 2.4 | Srebp1 | -2.1 | -5.0 | -2.0 | |
| 0.75 | none | NS | 1.7 | NS | |
| 1.5 | none | NS | NS | NS |
Negative sign indicates upper condition is suppressed.
**p<0.01
*p<0.05, nd-not detected, NS-response not significant.
, pattern shown by oleate pathway genes that are mediated by Srebp-1c, distinguished by direct suppression by GVAD; ; pattern shown by cholesterol pathway genes that are mediated by Srebp2, No inhibition by GVAD, reversal of Cyp1b1-/- effects by GVAD. The pattern does not prove involvement of these mediators for genes not previously studied.
Stellate cell markers are elevated in liver at birth by GVAD and Cyp1b1 deletion.
| Fold Change | Relative Expression (Cy3 x103) | ||||
|---|---|---|---|---|---|
| WT GVAD | Birth | Weaning | Adult | ||
| WT Suff | WT Suff | ||||
| -2.5 | -8.8 | 31.0 | 4.5 | 17.6 | |
| 1.7 (p = .07) | 2.2 | 0.35 | 0.8 | 0.1 | |
| 3.4 | 3.9 | 0.9 | 1.3 | 0.1 | |
| 2.6 | 4.6 | 4.7 | 7.0 | 1.5 | |
| 2.8 | 2.5 | 2.9 | 4.2 | 0.5 | |
| 2.5 | 2.0 | 0.5 | 0.4 | 0.1 | |
| 2.4 | 2.0 | 0.6 | 0.5 | 0.4 | |
| 2.5 | 2.0 | 0.3 | 0.2 | 0.08 | |
| 2.0 | 1.3 | 0.3 | 0.2 | 0.2 | |
| 1.7 | 1.9 | 2.4 | 2.9 | 2.0 | |
| 1.8 | 1.6 | 0.2 | 0.3 | 0.09 | |
| 2.1 | 4.0 | 0.2 | 0.2 | 0.07 | |
| 2.6 | 1.5 | 0.15 | 0.3 | 0.04 | |
| 2.6 | 1.4 | 0.7 | 0.7 | 0.08 | |
| -1.5 | -1.5 | 0.1 | 0.2 | 0.4 | |
| ns | ns | 0.4 | 0.8 | 1.0 | |
| n.s. | n.s. | 0.4 | 0.3 | 0.1 | |
| n.s | n.s | 5.0 | 2.3 | 7.0 | |
| n.s | n.s | 0.4 | 0.8 | 1.5 | |
| n.s | n.s | 1.3 | 3.1 | 1.9 | |
| n.s. | -2.5 | 2.1 | 1.1 | 0.8 | |
| n.s. | -2.0 | 0.8 | 13.0 | 61.3 | |
| n.s. | 1.7 | 0.01 | 0.09 | 0.5 | |
| n.s. | n.s. | 288 | 257 | 250 | |
| n.s | n.s | 25.7 | 8.7 | 2.2 | |
| n.s | -4.5 | 0.5 | < .01 | < .01 | |
a Weaning: pnd 21; Adult: pnd 98.
*p-value ≤ 0.05
** p-value ≤ 0.01
01 p = 0.1
Fig 2Effects of GVAD and Cyp1b1 deletion on liver retinoid content and gene expression at birth and weaning.
PCR determinations of expression (dCt) for individual WT and Cyp1b1-/- mice from multiple litters at PN21: Aldh1a1, Rdh11, Scd1, and Hmgcr (A). Correlations for expression versus body weight for WT and Cyp1b1-/- mice (B). Liver retinol and retinyl ester content at birth in WT (open circles) and Cyp1b1-/- (solid circles) vitamin A-sufficient (Suff; black) and GVAD (red) mice were measured on the pooled livers from separate litters (C). Equivalent measurements on livers from individual WT and Cyp1b1-/- at weaning/PN21 pups (D). Correlation of GVAD and Cyp1b1-/- effects on stellate markers at birth (C). Correlation between Col1a1 expression and Sma1 and then other stellate activation markers at birth for expression in individual mice across the four treatments shown in Table 2 (E). Parts C and D were previously presented as separate supplementary figures [5]. *p-value ≤ 0.05, **p-value ≤ 0.01, ***p-value ≤ 0.001.
Fig 9Dual Cyp1b1/retinol regulation of Srebp-1c/oleate and Srebp2/cholesterol pathways in postnatal liver.
Pathways that convert acetate to cholesterol or oleoyl-CoA and retinaldehyde to RA or retinyl esters. All processes are inhibited in Cyp1b1-/- pups (KO) (Table 1). Srebp2/cholesterol pathway genes and Aldh1a1 show no effect of GVAD in WT pups. The Srebp-1/oleoyl-CoA pathway genes show losses with GVAD treatment of WT pups. The retinaldehyde is formed in the liver from β-carotene by Bco1. The reductase, Rdh11, which regenerates retinol, follows the Srebp1 pattern. This step, followed by Lrat, generates retinyl esters in stellate cells. Aldh1a1 is the major means to convert retininaldehyde to RA (A). Distinctive Cyp1b1 –retinol partnerships for Srebp1 and Srebp2 during stimulations by Igf1. Inhibition Pathway (I): Cyp1b1 removes/metabolizes the mediator of an inhibitory pathway, which becomes active in Cyp1b1-/- pups. Retinol supports this inhibitory pathway, leading to stimulation with GVAD in Cyp1b1-/- pups, but no effect in WT, where Cyp1b1 removes the mediator. Activator Pathway (A): Retinol stimulates an Activator Pathway that leads to the suppression by GVAD in WT pups. A contribution of Cyp1b1 to activation is possible, but Cyp1b1-/- Activator losses cannot be distinguished from enhancement of the Inhibitor Pathway. TORC1 activation and Insig inhibition control the Scap-Srebp complex that is suppressed by cholesterol (CH) (B).